LUMIGAN Drug Patent Profile

When do Lumigan patents expire, and what generic alternatives are available?

Lumigan is a drug marketed by Abbvie and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has thirty-four patent family members in twenty-two countries.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumigan

A generic version of LUMIGAN was approved as bimatoprost by APOTEX on December 1^st, 2014.

Summary for LUMIGAN

International Patents:	34
US Patents:	1
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	47
Patent Applications:	4,874
Drug Prices:	Drug price information for LUMIGAN
Drug Sales Revenues:	Drug sales revenues for LUMIGAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMIGAN
What excipients (inactive ingredients) are in LUMIGAN?	LUMIGAN excipients list
DailyMed Link:	LUMIGAN at DailyMed

See drug prices for LUMIGAN

See drug sales revenues for LUMIGAN

Recent Clinical Trials for LUMIGAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Amneal Pharmaceuticals, LLC	PHASE1
CBCC Global Inc.	PHASE1
Amneal EU, Limited	PHASE1

See all LUMIGAN clinical trials

Pharmacology for LUMIGAN

Drug Class

Prostaglandin Analog

Paragraph IV (Patent) Challenges for LUMIGAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUMIGAN	Ophthalmic Solution	bimatoprost	0.01%	022184	1	2011-04-05
LUMIGAN	Ophthalmic Solution	bimatoprost	0.03%	021275	1	2008-12-22

US Patents and Regulatory Information for LUMIGAN

LUMIGAN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010	AB	RX	Yes	Yes			Y	Y
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	021275-001	Mar 16, 2001		DISCN	Yes	No

Expired US Patents for LUMIGAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	021275-001	Mar 16, 2001
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010

EU/EMA Drug Approvals for LUMIGAN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Lumigan	bimatoprost	EMEA/H/C/000391Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,	Authorised	no	no	no	2002-03-08

International Patents for LUMIGAN

See the table below for patents covering LUMIGAN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0825980	UTILISATION DE DERIVES D'ACIDE CYCLOPENTANE HEPTAN(ENE)OIQUE, 2-HETEROARYLALKENYLE EN TANT QU'AGENTS THERAPEUTIQUES POUR LE TRAITEMENT DE L'HYPERTENSION OCULAIRE (CYCLOPENTANE HEPTAN(ENE)OIC ACID, 2-HETEROARYLAKENYL DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF OCULAR HYPERTENSION)
South Korea	101177598
Japan	2014144983	ENHANCED BIMATOPROST OPHTHALMIC SOLUTION

Supplementary Protection Certificates for LUMIGAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	CA 2002 00020	Denmark
0660716	SPC023/2002	Ireland		SPC023/2002: 20040929, EXPIRES: 20170307
0660716	02C0033	France		PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:

Market Dynamics and Financial Trajectory for LUMIGAN (Bimatoprost)

Last updated: February 20, 2026

What is the current market position of LUMIGAN?

LUMIGAN (bimatoprost ophthalmic solution 0.03%) is a leading treatment for elevated intraocular pressure in glaucoma and ocular hypertension. It generated global sales of approximately USD 600 million in 2022. The drug is marketed by AbbVie following its acquisition of Allergan in 2020. LUMIGAN maintains a dominant position in the prostaglandin analog segment due to its efficacy, safety profile, and once-daily dosing.

How does the competitive landscape influence LUMIGAN?

The glaucoma drug market includes:

• Bimatoprost (LUMIGAN)
• Latanoprost (Xalatan)
• Travoprost (Travatan Z)
• Tafluprost (Zioptan)

Market share, based on sales, favors LUMIGAN at roughly 40%. Latanoprost holds approximately 30%, with others sharing the remainder. The competition focuses on efficacy, side effects (e.g., iris pigmentation, eyelash growth), and cost.

What are the key drivers of demand and growth?

• Prevalence of glaucoma: Projected to reach 120 million globally by 2025 [1], increasing demand.
• Aging population: Age-related risks favor increased treatment rates in developed nations.
• Patient adherence: Once-daily dosing improves compliance, supporting sustained sales.
• Line extensions and indications: Bimatoprost has been approved for eyelash enhancement (Latisse), expanding market potential.

How have recent patent and regulatory developments affected the market?

LUMIGAN held patent protection until 2023 in several markets, with the US patent expiring in 2020. This led to generic entry, causing sales erosion. However, AbbVie introduced a branded mini-dose (LUMIGAN Ultra) and combination therapies to maintain competitiveness.

The FDA approved a 0.01% concentration for LUMIGAN in 2019 for better tolerability, improving patient retention.

What is the outlook for LUMIGAN’s financial trajectory?

Forecasts suggest:

• Short term (2023-2025): Sales decline expected due to generic competition, with estimates dropping to USD 300–400 million annually.
• Mid to long term (2026-2030): Growth driven by expanded indications (e.g., eyelash growth), formulations with improved tolerability, and new combination options.
• Emerging markets: Growth in Asia-Pacific and Latin America expected at compounded annual growth rates (CAGR) of approximately 8%.

What factors could threaten or boost LUMIGAN sales?

Threats:

• Generic drugs from multiple manufacturers reducing brand loyalty.
• Price competition and biosimilar emergence.
• Newer drug classes, such as Rho kinase inhibitors, providing alternative treatments.

Boosters:

• Expand drug indications.
• Develop alternative formulations (once-daily, sustained-release eye drops).
• Capitalize on the eyelash growth market with Latisse.

How do R&D investments influence future revenue prospects?

AbbVie and competitors invest in:

• Novel prostaglandin derivatives with improved efficacy or safety.
• Combination therapies reducing dosing complexity.
• Delivery system innovations, such as sustained-release devices.

R&D spending signifies a focus on extending product lifecycle and addressing market saturation issues.

Summary Table: LUMIGAN Market and Financial Data

Aspect	Data	Source
2022 global sales	USD 600 million	[1]
Market share (glaucoma segment)	Approximately 40%	[2]
Patent expiry in US	2020	[3]
Predicted growth (2023-2025)	20-30% decline due to generics	Industry estimates
Long-term growth drivers	Eyelash extension, combination therapies, formulations	Analyst reports
Emerging market CAGR	8% in Asia-Pacific and Latin America	[4]

Key Takeaways

• LUMIGAN is the leading prostaglandin analog in glaucoma therapy, with USD 600 million in 2022 sales.
• Patent expiry in 2020 led to significant generic competition, causing near-term sales decline.
• Future growth hinges on expanding indications, formulation innovations, and penetration into emerging markets.
• Competitive pressures from biosimilars and new drug classes remain significant risks.
• R&D investments aim to extend product lifecycle and develop next-generation therapies.

FAQs

1. How does LUMIGAN compare to other glaucoma treatments?
LUMIGAN offers once-daily dosing and a favorable safety profile, giving it an advantage over some competitors. It has a strong position in the prostaglandin analog class but faces price competition from generics.

2. When will generic versions of LUMIGAN impact sales significantly?
Generic entry occurred in most markets starting in 2020, with full market penetration expected by 2023, leading to a substantial sales decline in the short term.

3. What new formulations are under development for LUMIGAN?
AbbVie is exploring sustained-release implants and combination therapies designed to improve efficacy, adherence, and tolerability.

4. Can LUMIGAN expand into new therapeutic areas?
Yes. The eyelash growth application under Latisse has expanded its market beyond ocular hypertension and glaucoma, creating additional revenue streams.

5. How is the emerging market growth expected to influence LUMIGAN sales?
High glaucoma prevalence and increasing healthcare spending in Asia-Pacific and Latin America support CAGR estimates of approximately 8%, contributing to the longer-term sales stabilization.

---

References

[1] International Agency for the Prevention of Blindness. (2022). Global Data on Glaucoma.
[2] IQVIA. (2022). Market Share Report – Ophthalmic Drugs.
[3] U.S. Food and Drug Administration. (2020). Patent and Exclusivity Expiry Dates.
[4] Fitch Solutions. (2022). Asia-Pacific Pharmaceutical Market Outlook.